PRTA - プロセナ （Prothena Corporation plc）PRTAのニュース
Prothena adds former FDA neuro chief Billy Dunn to director board 2023/05/17 16:13:55 Seeking Alpha
Alzheimer''s drug developer Prothena (PRTA) announced Tuesday that Billy Dunn, who previously led the FDA''s Office of Neuroscience, is joining its board. Read more here.
Prothena Corporation plc: Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors 2023/05/16 20:12:00 Finanz Nachrichten
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced today…
Prothena Biosciences'' Unique Approach To Protein Misfolding Could Be The Future 2023/05/07 06:28:01 Seeking Alpha
Prothena''s recent collaboration with Walgreens is expected to drive recruitment for Prothena''s ongoing ASCENT-2 safety and tolerability trial of PRX012. Click here to read more.
BofA Securities maintains Prothena at Buy with a price target of $85.00 2023/05/05 16:23:37 Investing.com
https://www.investing.com/news/pro/prothena-corp-receives-investment-bank-analyst-rating-update-3074646
Recap: Prothena Corp Q1 Earnings 2023/05/04 21:05:33 Benzinga
Prothena Corp (NASDAQ: PRTA ) reported its Q1 earnings results on Thursday, May 4, 2023 at 04:05 PM. Here''s what investors need to know about the announcement. Earnings Prothena Corp beat estimated earnings by 5.32%, reporting an EPS of $-0.89 versus an … Full story available on Benzinga.com
Prothena: I''m Not A Buyer At A $3 Billion Valuation 2023/02/08 11:32:52 Seeking Alpha
Prothena’s pipeline has several high-value assets which may trigger several milestone payments and royalties. See why I am rating PRTA stock as a Sell.
Prothena Corporation plc: Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2023/02/03 21:06:00 Finanz Nachrichten
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today ann…
Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2023/02/03 21:05:00 Business Wire
DUBLIN--(BUSINESS WIRE)--Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Prothena says Alzheimer’s candidate was safe in early-stage trial (NASDAQ:PRTA) 2023/01/31 21:56:29 Seeking Alpha
Prothena (PRTA) announced Tuesday that PRX005, an Alzheimer''s candidate it develops with Bristol Myers (BMY), was safe and well tolerated in a Phase 1 trial Read the full story here.
Prothena Corporation plc: Prothena Reports Topline Phase 1 Single Ascending Dose Study Results of PRX005, a Novel Anti-MTBR-Tau Antibody for the Potential Treatment of Alzheimer''s Disease 2023/01/31 21:12:00 Finanz Nachrichten
Results from a single ascending dose (SAD) study in healthy volunteers demonstrated dose-proportional PRX005 concentrations in plasma with robust central nervous system (CNS) penetration of this p…
These strategies will help Prothena Corporation plc (PRTA) succeed 2022/12/01 15:32:00 US Post News
In Wednesday’s session, Prothena Corporation plc (NASDAQ:PRTA) marked $62.51 per share, up from $58.12 in the previous session. While Prothena Corporation plc has overperformed by 7.55%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PRTA rose by 24.65%, with highs and lows ranging from $65.35 to […]
This Insider Just Sold Shares of Prothena Corp PLC 2022/11/27 18:30:05 GuruFocus
Related Stocks: PRTA ,
Roche''s Alzheimer''s Drug Fails In Phase 3; Here''s The Fallout For Biogen, Lilly, Prothena And Others 2022/11/14 14:17:46 Investor''s Business Daily
Roche said its experimental Alzheimer''s treatment failed in two final-phase studies, leading Biogen stock to surge while others crumbled.